D0816 | bromocriptine mesylate
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 11.19±2.78 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 13.5 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 12.57±1.60 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
   |
Warning |
Aggregated GHS information provided by 11 companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. Reported as not meeting GHS hazard criteria by 1 of 11 companies. For more detailed information, please visit ECHA C&L website Of the 5 notification(s) provided by 10 of 11 companies with hazard statement code(s): H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral] H332 (40%): Harmful if inhaled [Warning Acute toxicity, inhalation] H361 (50%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] H400 (50%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard] H410 (80%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P261, P264, P270, P271, P273, P281, P301+P312, P304+P312, P304+P340, P308+P313, P312, P330, P391, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| (+)-Bromocriptine methanesulfonate | (5'a)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione mesylate | (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman methanesulfonate |
| (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman methanesulfonate (salt) | (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman methanesulfonate | (5xi,5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman methanesulfonate (salt) |
| (5xi,5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman methanesulfonate (salt) | (6aR,9R)-5-Bromo-N-[(2R,5S,10aS,10bS)-10b-hydroxy-2-(1-methylethyl)-5-(2-methylpropyl)-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quin | .alpha.-Ergocryptine, methanesulfonate |
| 2-Bromine-alpha-ergocryptine methanesulfonate | 2-Bromo alpha-Ergocryptine Mesylate | 2-Bromo-.alpha.-ergocryptine monomethanesulfonate |
| 2-Bromo-12'-hydroxy-5'alpha-isobutyl-2'-isopropylergotaman-3',6',18-trione monomethanesulphonate | 2-Bromo-a-ergocryptine methanesulfonate salt | 2-Bromo-alpha-ergocryptine mesylate |
| 2-Bromo-alpha-ergocryptine methanesulfonate | 2-Bromo-alpha-ergokryptine-mesilate | 2-Bromo-alpha-ergokryptine-mesilate [German] |
| 2-Bromoergocryptine Mesylate | 2-Bromoergocryptine monomethanesulfonate (salt) | 2-bromo-12'-hydroxy-5'a-isobutyl-2'-isopropylergotaman-3',6',18-trione monomethanesulphonate; |
| 22260-51-1 | 93201-EP2272825A2 | 93201-EP2305633A1 |
| AKOS015896276 | B 2134 | B6298 |
| BROMOCRIPTINE MESYLATE | Bagren | Bromergon |
| Bromocriptine (mesylate) | Bromocriptine mesilate | Bromocriptine mesilate (JP17) |
| Bromocriptine mesylate (USP) | Bromocriptine mesylate [USAN:USP] | Bromocriptine mesylate [USAN] |
| Bromocriptine methanesulfonate | Bromocryptine mesylate | Bromocryptine methanesulfonate |
| C32H40BrN5O5.CH3SO3H | C32H40BrN5O5.CH4O3S | CAS-22260-51-1 |
| CB 154 | CB 154 methanesulfonate (salt) | CB-154 |
| CB-154 mesylate | CCG-220121 | CCG-221475 |
| CHEBI:3182 | CHEMBL1200503 | CS-6048 |
| Cycloset | D00780 | DSSTox_CID_197 |
| DSSTox_GSID_20197 | DSSTox_RID_75426 | DTXSID6020197 |
| EINECS 244-881-1 | EU-0100171 | Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)- |
| FFP983J3OD | HMS1568I04 | HMS3260D03 |
| HMS3411K09 | HMS3675K09 | HMS3712I04 |
| HY-12705A | LP00171 | LS-7234 |
| NCGC00257268-01 | NCGC00260856-01 | NOJMTMIRQRDZMT-GSPXQYRGSA-N |
| NSC-169774 | NSC169774 | Parlodel |
| Parlodel (TN) | Pravidel | Prestwick_771 |
| Q27105974 | SCHEMBL40559 | SR-01000075356 |
| SR-01000075356-1 | SR-01000597796 | SR-01000597796-1 |
| SR-01000597796-2 | Tox21_303597 | Tox21_500171 |
| UNII-FFP983J3OD | alpha-Ergocryptine, 2-bromo-, methanesulfonate | oline-9-carboxamide methanesulfonate |